Lévi-Dan Azoulay

Lévi-Dan Azoulay

Auto-generated profile, based on publicly available information

Lévi-Dan Azoulay

Internal Medicine Department 2, French Referral Center for Histiocytoses Assistance Publique–Hôpitaux de Paris Pitié–Salpêtrière Hospital, Sorbonne Université, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
LALévi-Dan Azoulay
Lévi-Dan Azoulay
MBMarine Bravetti
Marine Bravetti
FCFleur Cohen-Aubart
Fleur Cohen-Aubart
JEJean-François Emile
Jean-François Emile
DSDanielle Seilhean
Danielle Seilhean
JHJulien Haroche
Julien Haroche
Cardiac involvement of Erdheim–Chester disease (ECD), a rare L group histiocytosis, has been reported to be associated with poor outcomes, but systematic studies are lacking. The present study aimed to investigate the prevalence, clinical features, imaging features, and prognosis of cardiac involvement in ECD in a large series. All patients with ECD who underwent cardiac magnetic resonance (CMR) imaging between 2003 and 2019 at a French tertiary center were retrospectively included. Primary outcome was all-cause mortality. Secondary outcomes were pericarditis, cardiac tamponade, conduction disorders, device implantation and coronary artery disease (CAD). A total of 200 patients were included [63 (54–71) years, 30% female, 58% BRAFV600E mutated]. Median follow-up was 5.5 years (3.3–9 years). On CMR, right atrioventricular sulcus infiltration was observed in 37% of patients, and pericardial effusion was seen in 24% of patients. In total, 8 patients (4%) had pericarditis (7 acute, 1 constrictive), 10 patients (5%) had cardiac tamponade, 5 patients (2.5%) had ECD-related high-degree conduction disorders, and 45 patients (23%) had CAD. Overall, cardiac involvement was present in 96 patients (48%) and was associated with BRAFV600E mutation [Odds ratio (OR) = 7.4, 95% confidence interval (CI) (3.5–16.8), P < 0.001] and ECD-related clinical events [OR = 5, 95%CI (1.5–21.2), P = 0.004] but not with lower survival in multivariate analysis [adjusted hazard ratio (HR) = 1.4, 95% CI (0.8–2.5), P = 0.2]. Cardiac involvement is present in nearly half of ECD patients and is associated with BRAFV600E mutation and complications (pericarditis, cardiac tamponade, and conduction disorders) but not with lower survival. More than half of ECD patients had evidence of cardiac involvement on CMR, which was associated with a higher risk of clinical events. Abbreviations: CMR cardiac magnetic resonance; ECD, Erdheim–Chester disease; HR, hazard ratio; OR, odds ratio.

1 July 2025 in Lupus
Verified
Journal Article
Closed access
LALévi-Dan Azoulay
Lévi-Dan Azoulay
TBThomas Broussaud
Thomas Broussaud
NKNadjia Kachenoura
Nadjia Kachenoura
AMAlexis Mathian
Alexis Mathian
MPMicheline Pha
Micheline Pha
ZAZahir Amoura
Zahir Amoura
Background: Assessment of contemporary cardiovascular risk scores using clinically relevant endpoints is lacking in systemic lupus erythematosus (SLE). Aim: This study aimed to assess and compare the performances of SCORE2, QRISK3 and PREVENT equations in SLE. Methods: SLE patients with no prior atherosclerotic cardiovascular disease (ASCVD) who underwent a baseline cardiovascular risk assessment including coronary artery calcium (CAC) scoring at the French national SLE reference center between 2014 and 2024 were retrospectively included. The primary outcome was incident ASCVD events defined as coronary artery disease (CAD), stroke and peripheral artery disease (PAD). The secondary outcome was CAC presence (CAC score >0). Discrimination and calibration were respectively assessed by areas under the curve (AUCs) and observed-to-predicted risk ratios. Results: A total of 143 patients were included (91% female, median age 51 years [46–60], SLE duration 15 years [8–22]). After a median follow-up of 7 years [3–9], 12 patients (8%) had incident ASCVD events (7 CAD, 4 strokes, 1 PAD). AUCs were 0.81 for SCORE2, 0.76 for QRISK3 and 0.80 for PREVENT and did not significantly differ (all p > .05). Optimal thresholds for clinical events prediction were 3.9% for SCORE2, 9.4% for QRISK3 and 4.3% for PREVENT. Mean observed-to-predicted ratios were 3 for SCORE2, 0.85 for QRISK3 and 2.8 for PREVENT. Similar results were obtained when using CAC as the main outcome. Conclusion: Risk scores demonstrated similar and fair discriminative performances but were poorly calibrated except for QRISK3. Application of lower thresholds and use of QRISK3 may improve cardiovascular risk stratification in SLE but requires confirmation from larger studies.

23 January 2024 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
LAL.-D. Azoulay
L.-D. Azoulay
AHA.-L. Houist
A.-L. Houist
EFE. Feredj
E. Feredj
WVW. Vindrios
W. Vindrios
SGS. Gallien
S. Gallien

19 December 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
LALévi-Dan Azoulay
Lévi-Dan Azoulay
NKNadjia Kachenoura
Nadjia Kachenoura
SBSamia Boussouar
Samia Boussouar
ECEtienne Charpentier
Etienne Charpentier
AGAlain Giron
Alain Giron
ARAlban Redheuil
Alban Redheuil

29 August 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
LALévi-Dan Azoulay
Lévi-Dan Azoulay
NKNadjia Kachenoura
Nadjia Kachenoura
SBSamia Boussouar
Samia Boussouar
ECEtienne Charpentier
Etienne Charpentier
NPNicoletta Pasi
Nicoletta Pasi
ARAlban Redheuil
Alban Redheuil

12 October 2023 in Blood Advances
Verified
Journal Article
Open access
PDF file
LALévi-Dan Azoulay
Lévi-Dan Azoulay
MBMarine Bravetti
Marine Bravetti
FCFleur Cohen-Aubart
Fleur Cohen-Aubart
JEJean-François Emile
Jean-François Emile
FCFrédéric Charlotte
Frédéric Charlotte
JHJulien Haroche
Julien Haroche